Clinical Trials Logo

Gray Zone Lymphoma clinical trials

View clinical trials related to Gray Zone Lymphoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01943682 Completed - Clinical trials for Acute Myeloid Leukemia

Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma

Start date: September 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of a study drug called CPX-351. This drug has been tested in adults but not yet in children and adolescents. This study tests different doses of the drug to see which dose is safer in children and adolescents. Patients who have blood cancer are being asked to take part in this study . Blood cancers may include leukemia and lymphoma. Patients able to be in this study have already been treated with standard chemotherapy for their disease and the disease is still growing or has come back. CPX-351 is a drug that is not yet approved by the United States Food and Drug Administration (FDA) and is only used in research studies like this one. CPX-351 is made up of two chemotherapy drugs that patients may have already received called cytarabine and daunorubicin that are now packaged together. Another purpose of this study is to collect blood samples for special research studies. Researchers want to study how much of the CPX-351 is in the body over time. These studies are call pharmacokinetic studies or PK studies for short. PK studies require the collection of several blood samples before and after participants are given the study drug.

NCT ID: NCT01665768 Completed - Clinical trials for Mantle Cell Lymphoma

Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma

Start date: September 2012
Phase: Phase 2
Study type: Interventional

This research is being done to determine if combining an investigational drug called Everolimus with Rituximab can reduce the risk of your cancer from returning after high dose chemotherapy.

NCT ID: NCT00001337 Completed - Burkitt Lymphoma Clinical Trials

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Start date: May 8, 1993
Phase: Phase 2
Study type: Interventional

5-Drug Combination Chemotherapy with Hematologic Toxicity Attenuation. EPOCH: Etoposide, VP-16, NSC-141540; Prednisone, PRED, NSC-10023; Vincristine, VCR, NSC-67574; Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; with Granulocyte Colony-Stimulating Factor (Amgen), G-CSF, NSC-614629....